ArticlePloS one2015
Optimization of Drug Delivery by Drug-Eluting Stents.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- Long-term (2-5 years) adverse clinical outcomes associated with ZES versus SES, PES and EES: A Meta-Analysis.Scientific reports · 2017Pooled it
- A Comprehensive Numerical Simulation on the Safety and Efficacy of Circular-Versus Trapezoidal-Shaped Intravascular Drug-Eluting Stents.International journal for numerical methods in biomedical engineering · 2026Article
- State-of-the-Art Review on Finite Element Analysis Applied to Ultrathin-Strut Drug-Eluting Stents: Examining the Present and Looking Ahead to the Future.Bioengineering (Basel, Switzerland) · 2026Review
- A Bibliometric Analysis of Strategies for Atherosclerosis Treatment with Organic Nanoparticles.Pharmaceutics · 2025Review
- Advancements in Coronary Bifurcation Stenting Techniques: Insights From Computational and Bench Testing Studies.International journal for numerical methods in biomedical engineering · 2025Review
- A Meta-Analysis of 3-Year Outcomes of Drug-Coated Balloons Versus Drug-Eluting Stents for Small-Vessel Coronary Artery Disease.JACC. Advances · 2024Article
- Efficacy and Safety Evaluation of Tacrolimus-Eluting Stent in a Porcine Coronary Artery Model.Tissue engineering and regenerative medicine · 2024Article
- Evolving Diagnostic and Management Advances in Coronary Heart Disease.Life (Basel, Switzerland) · 2023Review
- Drug-Eluting Stents: Technical and Clinical Progress.Biomimetics (Basel, Switzerland) · 2023Review
- Modeling Dual Drug Delivery from Eluting Stents: The Influence of Non-Linear Binding Competition and Non-Uniform Drug Loading.Pharmaceutical research · 2023Article
- Understudied factors in drug-coated balloon design and evaluation: A biophysical perspective.Bioengineering & translational medicine · 2023Review
- Review
- Assessment of structural, biological and drug release properties of electro-sprayed poly lactic acid-dexamethasone coating for biomedical applications.Biomedical engineering letters · 2021Article
- Design optimization of a cardiovascular stent with application to a balloon expandable prosthetic heart valve.Materials & design · 2021Article
- The Use of Bioactive Polymers for Intervention and Tissue Engineering: The New Frontier for Cardiovascular Therapy.Polymers · 2021Review
- Hemodynamic Impact of Stenting on Carotid Bifurcation: A Potential Role of the Stented Segment and External Carotid Artery.Computational and mathematical methods in medicine · 2021Article
- Effect of Novel Polymer-Free Nitrogen-Doped Titanium Dioxide Film-Coated Coronary Stent Loaded With Mycophenolic Acid.Frontiers in bioengineering and biotechnology · 2021Article
- Development of a Bioactive Polymeric Drug Eluting Coronary Stent Coating Using Electrospraying.Annals of biomedical engineering · 2020Article
- Targeted Delivery of Bioactive Molecules for Vascular Intervention and Tissue Engineering.Frontiers in pharmacology · 2018Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-eluting stents (DES), which release anti-proliferative drugs into the arterial wall in a controlled manner, have drastically reduced the rate of in-stent restenosis and revolutionized the treatment of atherosclerosis. However, late stent thrombosis remains a safety concern in DES, mainly due to delayed healing of the endothelial wound inflicted during DES implantation. We present a framework to optimize DES design such that restenosis is inhibited without affecting the endothelial healing process. To this end, we have developed a computational model of fluid flow and drug transport in stented arteries and have used this model to establish a metric for quantifying DES performance. The model takes into account the multi-layered structure of the arterial wall and incorporates a reversible binding model to describe drug interaction with the cells of the arterial wall. The model is coupled to a novel optimization algorithm that allows identification of optimal DES designs. We show that optimizing the period of drug release from DES and the initial drug concentration within the coating has a drastic effect on DES performance. Paclitaxel-eluting stents perform optimally by releasing their drug either very rapidly (within a few hours) or very slowly (over periods of several months up to one year) at concentrations considerably lower than current DES. In contrast, sirolimus-eluting stents perform optimally only when drug release is slow. The results offer explanations for recent trends in the development of DES and demonstrate the potential for large improvements in DES design relative to the current state of commercial devices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.